Search results
FDA panel backs Eli Lilly’s Alzheimer’s drug
The Hill· 1 hour agoA federal advisory panel on Monday voted in favor of recommending Eli Lilly’s new drug that is under consideration for its potential to slow the...
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
CNBC· 4 hours agoEli Lilly & Co.'s shares climbed in early US trading after its experimental drug for Alzheimer's...
FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug
Investor's Business Daily· 2 hours agoEli Lilly stock jumped Monday after advisors to the Food and Drug Administration said the benefits...
Eli Lilly exec expects obesity pill data in April 2025
WHTC 1450 Holland· 2 hours ago(Reuters) - Data from Eli Lilly's late stage trial on experimental obesity pill orforglipron is...
Alzheimer’s drug from Eli Lilly wins backing of FDA committee
Washington Post· 3 hours agoAn advisory committee to the Food and Drug Administration on Monday endorsed an Alzheimer’s drug...
Alzheimer's drug that can slow disease gets backing from FDA advisers
KETV 7 Omaha· 50 minutes agoA closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval ...
Eli Lilly exec says seeing out of pocket payments for obesity drug in US
WSAU Wausau· 3 hours ago(Reuters) - A top Eli Lilly executive said on Monday that more patients are paying the full list...
Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan'
Yahoo Finance via AOL· 5 hours agoEli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound —...
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks via Yahoo Finance· 11 hours agoEli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a...
Shell Asset Management Co. Sells 12,465 Shares of Eli Lilly and Company (NYSE:LLY)
ETF DAILY NEWS· 11 hours agoShell Asset Management Co. lessened its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 21.7% in the fourth quarter, Holdings Channel.com ...